Improving treatment outcomes for MDR-TB - Novel host-directed therapies and personalised medicine of the future

Multidrug-resistant TB (MDR-TB) is a major threat to global health security. In 2017, only 50% of patients with MDR-TB who received WHO-recommended treatment were cured. Most MDR-TB patients who recover continue to suffer from functional disability due to long-term lung damage. Whilst new MDR-TB tre...

Descripción completa

Detalles Bibliográficos
Autores: Rao, Mangala|||0000-0002-0579-1097, Ippolito, Giuseppe|||0000-0002-1076-2979, Mfinanga, S., Ntoumi, F., Yeboah-Manu, Dorothy|||0000-0002-1663-6287, Vilaplana, Cristina|||0000-0002-2808-7270, Zumla, Alimuddin|||0000-0002-5111-5735, Maeurer, M.
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:223604
Acceso en línea:https://ddd.uab.cat/record/223604
https://dx.doi.org/urn:doi:10.1016/j.ijid.2019.01.039
Access Level:acceso abierto
Palabra clave:Biomarkers
Clinical studies
Host-directed therapies
Immunotherapy
Multidrug-resistant tuberculosis
Personalised medicine
id ES_a6faa8f7e198cc18e50dbf20fe4c8d08
oai_identifier_str oai:ddd.uab.cat:223604
network_acronym_str ES
network_name_str España
repository_id_str
spelling Improving treatment outcomes for MDR-TB - Novel host-directed therapies and personalised medicine of the futureRao, Mangala|||0000-0002-0579-1097Ippolito, Giuseppe|||0000-0002-1076-2979Mfinanga, S.Ntoumi, F.Yeboah-Manu, Dorothy|||0000-0002-1663-6287Vilaplana, Cristina|||0000-0002-2808-7270Zumla, Alimuddin|||0000-0002-5111-5735Maeurer, M.BiomarkersClinical studiesHost-directed therapiesImmunotherapyMultidrug-resistant tuberculosisPersonalised medicineMultidrug-resistant TB (MDR-TB) is a major threat to global health security. In 2017, only 50% of patients with MDR-TB who received WHO-recommended treatment were cured. Most MDR-TB patients who recover continue to suffer from functional disability due to long-term lung damage. Whilst new MDR-TB treatment regimens are becoming available, conventional drug therapies need to be complemented with host-directed therapies (HDTs) to reduce tissue damage and improve functional treatment outcomes. This viewpoint highlights recent data on biomarkers, immune cells, circulating effector molecules and genetics which could be utilised for developing personalised HDTs. Novel technologies currently used for cancer therapy which could facilitate in-depth understanding of host genetics and the microbiome in patients with MDR-TB are discussed. Against this background, personalised cell-based HDTs for adjunct MDR-TB treatment to improve clinical outcomes are proposed as a possibility for complementing standard therapy and other HDT agents. Insights into the molecular biology of the mechanisms of action of cellular HDTs may also aid to devise non-cell-based therapies targeting defined inflammatory pathway(s) in Mtb-driven immunopathology.Universitat Autònoma de Barcelona 22019-01-0120192019-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/223604https://dx.doi.org/urn:doi:10.1016/j.ijid.2019.01.039reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.https://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2236042026-06-06T12:50:31Z
dc.title.none.fl_str_mv Improving treatment outcomes for MDR-TB - Novel host-directed therapies and personalised medicine of the future
title Improving treatment outcomes for MDR-TB - Novel host-directed therapies and personalised medicine of the future
spellingShingle Improving treatment outcomes for MDR-TB - Novel host-directed therapies and personalised medicine of the future
Rao, Mangala|||0000-0002-0579-1097
Biomarkers
Clinical studies
Host-directed therapies
Immunotherapy
Multidrug-resistant tuberculosis
Personalised medicine
title_short Improving treatment outcomes for MDR-TB - Novel host-directed therapies and personalised medicine of the future
title_full Improving treatment outcomes for MDR-TB - Novel host-directed therapies and personalised medicine of the future
title_fullStr Improving treatment outcomes for MDR-TB - Novel host-directed therapies and personalised medicine of the future
title_full_unstemmed Improving treatment outcomes for MDR-TB - Novel host-directed therapies and personalised medicine of the future
title_sort Improving treatment outcomes for MDR-TB - Novel host-directed therapies and personalised medicine of the future
dc.creator.none.fl_str_mv Rao, Mangala|||0000-0002-0579-1097
Ippolito, Giuseppe|||0000-0002-1076-2979
Mfinanga, S.
Ntoumi, F.
Yeboah-Manu, Dorothy|||0000-0002-1663-6287
Vilaplana, Cristina|||0000-0002-2808-7270
Zumla, Alimuddin|||0000-0002-5111-5735
Maeurer, M.
author Rao, Mangala|||0000-0002-0579-1097
author_facet Rao, Mangala|||0000-0002-0579-1097
Ippolito, Giuseppe|||0000-0002-1076-2979
Mfinanga, S.
Ntoumi, F.
Yeboah-Manu, Dorothy|||0000-0002-1663-6287
Vilaplana, Cristina|||0000-0002-2808-7270
Zumla, Alimuddin|||0000-0002-5111-5735
Maeurer, M.
author_role author
author2 Ippolito, Giuseppe|||0000-0002-1076-2979
Mfinanga, S.
Ntoumi, F.
Yeboah-Manu, Dorothy|||0000-0002-1663-6287
Vilaplana, Cristina|||0000-0002-2808-7270
Zumla, Alimuddin|||0000-0002-5111-5735
Maeurer, M.
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Biomarkers
Clinical studies
Host-directed therapies
Immunotherapy
Multidrug-resistant tuberculosis
Personalised medicine
topic Biomarkers
Clinical studies
Host-directed therapies
Immunotherapy
Multidrug-resistant tuberculosis
Personalised medicine
description Multidrug-resistant TB (MDR-TB) is a major threat to global health security. In 2017, only 50% of patients with MDR-TB who received WHO-recommended treatment were cured. Most MDR-TB patients who recover continue to suffer from functional disability due to long-term lung damage. Whilst new MDR-TB treatment regimens are becoming available, conventional drug therapies need to be complemented with host-directed therapies (HDTs) to reduce tissue damage and improve functional treatment outcomes. This viewpoint highlights recent data on biomarkers, immune cells, circulating effector molecules and genetics which could be utilised for developing personalised HDTs. Novel technologies currently used for cancer therapy which could facilitate in-depth understanding of host genetics and the microbiome in patients with MDR-TB are discussed. Against this background, personalised cell-based HDTs for adjunct MDR-TB treatment to improve clinical outcomes are proposed as a possibility for complementing standard therapy and other HDT agents. Insights into the molecular biology of the mechanisms of action of cellular HDTs may also aid to devise non-cell-based therapies targeting defined inflammatory pathway(s) in Mtb-driven immunopathology.
publishDate 2019
dc.date.none.fl_str_mv 2
2019-01-01
2019
2019-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/223604
https://dx.doi.org/urn:doi:10.1016/j.ijid.2019.01.039
url https://ddd.uab.cat/record/223604
https://dx.doi.org/urn:doi:10.1016/j.ijid.2019.01.039
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869415741110878208
score 15.301603

Similares en LA Referencia